Christopher Pazdan - Repro Med Senior Operations
| KRMD Stock | USD 3.58 0.07 1.92% |
Executive
Christopher Pazdan is Senior Operations of Repro Med Systems
| Address | 100 Corporate Drive, Mahwah, NJ, United States, 07430 |
| Phone | 800 624 9600 |
| Web | https://www.korumedical.com |
Christopher Pazdan Latest Insider Activity
Tracking and analyzing the buying and selling activities of Christopher Pazdan against Repro Med stock is an integral part of due diligence when investing in Repro Med. Christopher Pazdan insider activity provides valuable insight into whether Repro Med is net buyers or sellers over its current business cycle. Note, Repro Med insiders must abide by specific rules, including filing SEC forms every time they buy or sell Repro Med'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Christopher Pazdan over three months ago Disposition of 54496 shares by Christopher Pazdan of Repro Med subject to Rule 16b-3 |
Repro Med Management Efficiency
The company has return on total asset (ROA) of (0.141) % which means that it has lost $0.141 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5025) %, meaning that it created substantial loss on money invested by shareholders. Repro Med's management efficiency ratios could be used to measure how well Repro Med manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Tangible Assets is expected to grow to -0.47. The current year's Return On Capital Employed is expected to grow to -0.41. At present, Repro Med's Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Non Currrent Assets Other is expected to grow to about 103.9 K, whereas Return On Tangible Assets are projected to grow to (0.47).Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| JD CCEP | AtriCure | 53 | |
| Marcena Clawson | Utah Medical Products | N/A | |
| Valerie StorchWillhaus | AtriCure | N/A | |
| James JD | Milestone Scientific | N/A | |
| JoAnne Alkire | Merit Medical Systems | N/A | |
| David Hissong | LeMaitre Vascular | N/A | |
| Jerod Funke | InfuSystems Holdings | 49 | |
| Ricardo Alvarez | Merit Medical Systems | N/A | |
| Brian JD | Merit Medical Systems | 63 | |
| Andy Molnar | Milestone Scientific | 62 | |
| Maik Helmers | LeMaitre Vascular | 50 | |
| Clay Schwabe | Precision Optics, | N/A | |
| Douglas Seith | AtriCure | 58 | |
| Mahesh Lawande | Precision Optics, | 51 | |
| Sarah Comstock | Merit Medical Systems | N/A | |
| Jeffrey DiRubio | Precision Optics, | N/A | |
| Brian Koopman | Utah Medical Products | 54 | |
| Brian Lloyd | Merit Medical Systems | 63 | |
| Jonathan Ngau | LeMaitre Vascular | 50 | |
| Jeanie Latz | InfuSystems Holdings | N/A | |
| Mark Fox | Utah Medical Products | N/A | |
Management Performance
| Return On Equity | -0.5 | ||||
| Return On Asset | -0.14 |
Repro Med Systems Leadership Team
Elected by the shareholders, the Repro Med's board of directors comprises two types of representatives: Repro Med inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Repro. The board's role is to monitor Repro Med's management team and ensure that shareholders' interests are well served. Repro Med's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Repro Med's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Linda Tharby, CEO President | ||
| Brian Case, Chief Officer | ||
| Thomas Adams, Chief Officer | ||
| Rob Cannon, Vice Sales | ||
| Josh Bennett, VP Devel | ||
| Kenneth Miller, Chief Officer | ||
| Tom Adams, Interim Officer | ||
| Christopher Pazdan, Senior Operations |
Repro Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Repro Med a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.5 | ||||
| Return On Asset | -0.14 | ||||
| Profit Margin | (0.38) % | ||||
| Operating Margin | (0.14) % | ||||
| Current Valuation | 162.74 M | ||||
| Shares Outstanding | 45.84 M | ||||
| Shares Owned By Insiders | 6.29 % | ||||
| Shares Owned By Institutions | 54.38 % | ||||
| Number Of Shares Shorted | 486.92 K | ||||
| Price To Earning | 11.56 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Repro Med Systems is a strong investment it is important to analyze Repro Med's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Repro Med's future performance. For an informed investment choice regarding Repro Stock, refer to the following important reports:Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Repro Med Systems. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Repro Med. If investors know Repro will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Repro Med listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.66) | Earnings Share (0.26) | Revenue Per Share 0.674 | Quarterly Revenue Growth 0.215 | Return On Assets (0.14) |
The market value of Repro Med Systems is measured differently than its book value, which is the value of Repro that is recorded on the company's balance sheet. Investors also form their own opinion of Repro Med's value that differs from its market value or its book value, called intrinsic value, which is Repro Med's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Repro Med's market value can be influenced by many factors that don't directly affect Repro Med's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Repro Med's value and its price as these two are different measures arrived at by different means. Investors typically determine if Repro Med is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Repro Med's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.